^
Association details:
| Biomarker: | PD-L1 overexpression + SOX2 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA
Published date:
11/06/2020
Excerpt:
ORR was higher in PD-L1 high patients with SOX2 low expression than SOX2 high expression…We found that SOX2 was an independent predictor for poor survival and resistance to anti-PD-1 therapy in melanoma with high PD-L1 expression.
DOI:
10.1136/jitc-2020-001037
